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The increasing resistance of clinical pathogens against the glycopeptide antibiotic vancomycin, a last-resort drug against infec-
tions with Gram-positive pathogens, is a major problem in the nosocomial environment. Vancomycin inhibits peptidoglycan
synthesis by binding to the D-Ala–D-Ala terminal dipeptide moiety of the cell wall precursor lipid II. Plasmid-transferable resis-
tance is conferred by modification of the terminal dipeptide into the vancomycin-insensitive variant D-Ala–D-Lac, which is pro-
duced by VanA. Here we show that exogenous D-Ala competes with D-Lac as a substrate for VanA, increasing the ratio of wild-
type to mutant dipeptide, an effect that was augmented by several orders of magnitude in the absence of the D-Ala–D-Ala
peptidase VanX. Liquid chromatography-mass spectrometry (LC-MS) analysis showed that high concentrations of D-Ala led to
the production of a significant amount of wild-type cell wall precursors, while vanX-null mutants produced primarily wild-type
precursors. This enhanced the efficacy of vancomycin in the vancomycin-resistant model organism Streptomyces coelicolor, and
the susceptibility of vancomycin-resistant clinical isolates of Enterococcus faecium (VRE) increased by up to 100-fold. The en-
hanced vancomycin sensitivity of S. coelicolor cells correlated directly to increased binding of the antibiotic to the cell wall. Our
work offers new perspectives for the treatment of diseases associated with vancomycin-resistant pathogens and for the develop-
ment of drugs that target vancomycin resistance.
Infectious diseases caused by multidrug-resistant (MDR) patho-gens are spreading rapidly and are among the biggest threats to
human health (1–4). A particular problem with drug discovery
from microbial sources is the high frequency of rediscovery of
known compounds, which necessitates new approaches to replen-
ish the antimicrobial drug pipelines (5–7). To deal with the in-
creasing antibiotic resistance, novel antibiotics are called for, or
alternatively, the life spans of the current drugs must be prolonged
by compounds counteracting resistance. Exemplary is amoxicil-
lin-clavulanic acid (Augmentin), which is a combination of a
-lactam antibiotic (amoxicillin) and a -lactamase inhibitor
(clavulanic acid) (8).
The cell wall and its biosynthetic machinery are a major target
of the action of clinical antibiotics, including fosfomycin, bacitra-
cin, cycloserine,-lactam antibiotics (penicillins and cephalospo-
rins), and glycopeptide antibiotics (vancomycin and teicoplanin)
(9–11). Enterococci and many other Gram-positive pathogenic
bacteria are resistant to a wide spectrum of antibiotics and can
often be treated only with specific -lactam antibiotics or with
vancomycin (12–14). Vancomycin resistance was first discovered
in the 1950s (15). Vancomycin resistance is exchanged between
bacteria via movable elements such as transposon Tn1546, which
is carried by many vancomycin-resistant enterococci (VRE) (16).
The most common forms of transferable vancomycin resistance
are the VanA- and VanB-type resistance, the expression of which
is inducible by vancomycin. VanA-type strains are resistant to
high levels of vancomycin as well as to another glycopeptide anti-
biotic, teicoplanin, while VanB-type strains show only inducible
resistance to vancomycin but retain susceptibility to teicoplanin
(17). While vancomycin resistance is most prevalent in entero-
cocci (18), resistance has spread to methicillin-resistant Staphylo-
coccus aureus (MRSA) (19).
Vancomycin targets the cell wall and prevents cell growth by
specifically binding to the D-alanyl–D-alanine (D-Ala–D-Ala) ter-
mini of the peptidoglycan (PG) precursor lipid II prior to its in-
corporation (20, 21). The terminal D-Ala–D-Ala dipeptide is al-
most universally conserved in bacteria, with the only exceptions
being D-Ala–D-Lac or D-alanyl–D-serine in strains with either nat-
ural or acquired resistance to vancomycin (22). The VanA-type
vancomycin resistance gene cluster in Streptomyces coelicolor con-
sists of seven genes in four different operons, vanRS, vanJ, vanK,
and vanHAX, which together mediate the substitution of the ter-
minal D-alanine (D-Ala) by D-lactate (D-Lac), thereby decreasing
the affinity of vancomycin for lipid II by three orders of magnitude
(15, 23). The vancomycin resistance gene cluster provides resis-
tance to both vancomycin and teicoplanin and is located on the
genome of the vancomycin producer Amycolatopsis mediterranei
(24, 25) as well as that of other actinomycetes, including the model
species Streptomyces coelicolor A3 (26, 27).
Streptomycetes are Gram-positive soil bacteria with a complex
multicellular life style (28–30). Streptomycetes are a major source
of antibiotics and many other natural products of medical and
biotechnological importance, such as anticancer, antifungal, or
herbicidal compounds (31, 32). Due to the competitive environ-
ment of the soil, these microorganisms readily exchange genetic
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material, including antibiotic biosynthetic clusters and antibiotic
resistance (33, 34). S. coelicolor is a nonpathogenic and genetically
tractable model system for vancomycin resistance, with a well-
annotated genome (35). The vancomycin resistance cluster of S.
coelicolor consists of vanRS, encoding a two-component regula-
tory system (TCS) consisting of sensory kinase VanS and response
regulator VanR, which together ensure the transcription of the
resistance genes in response to vancomycin challenge, and five
resistance genes in the order vanJKHAX, with vanHAX forming a
single transcription unit. Vancomycin-resistant enterococci clas-
sically carry vanRSHAX, the function of which is highly similar to
that in S. coelicolor, with the gene products VanH, VanA, and
VanX sharing 61%, 63%, and 64% amino acid identity, respec-
tively, while the TCS components VanR and VanS share 31% and
25% amino acid identity, respectively (27, 36). In response to
vancomycin at the cell membrane, VanRS ensure the induction of
the expression of vanHAX and in the case of S. coelicolor also vanK
and vanJ (37). VanH produces D-Lac from pyruvate (38), VanA is
a D-alanyl–D-lactate (D-Ala–D-Lac) ligase (39, 40), VanX hydro-
lyzes the D-Ala–D-Ala dipeptide and has been the target of previ-
ous studies assessing vancomycin sensitivity and resistance (36,
41), and VanK attaches glycine to lipid II with D-Lac as the termi-
nal residue (27, 42). VanJ is not required for vancomycin resis-
tance but is instead involved in the resistance to teicoplanin (43).
Importantly, VanA is a bifunctional enzyme, which besides D-
Ala–D-Lac can also produce the wild-type D-Ala–D-Ala dipeptide,
although this is negligible during vancomycin challenge (27, 42,
44, 45). In this work, we show that D-Ala, but not L-alanine (L-
Ala), acts as an inhibitor of the D-Ala–D-Lac ligase activity of
VanA, an effect which is visible in the presence of vancomycin-
sensitive and -resistant PG precursors. This effect was augmented
by several orders of magnitude in vanX-null mutants, effectively
sensitizing the strains to vancomycin. We propose that a combi-
nation of D-Ala with a VanX inhibitor could resensitize clinical
strains of VRE to vancomycin.
MATERIALS AND METHODS
Bacterial strains, culturing conditions, and MIC. Escherichia coli strains
JM109 (46) and ET12567 (47) were used for routine cloning procedures
and for extracting nonmethylated DNA, respectively. Cells of E. coli were
grown in Luria-Bertani broth (LB) at 37°C. Streptomyces coelicolorA3 (26)
M145 was the parent of all mutants described in this work. All media and
routine Streptomyces techniques were as described previously (47). Soy
flour mannitol (SFM) agar plates were used for propagating S. coelicolor
strains and to prepare spore suspensions. For liquid-grown cultures, S.
coelicolor mycelia were grown in normal minimal medium with phos-
phate (NMMP) supplemented with 1% (wt/vol) mannitol as the sole car-
bon source. The MICs of vancomycin against S. coelicolor M145 and its
mutant derivatives were determined by growth on minimal medium
(MM) agar plates supplemented with 1% mannitol as the sole carbon
source and 0, 2, 4, 8, 16, 32, 64, 128, 256, or 512 g ml1 vancomycin, in
combination with 0, 1, 5, 10, or 50 mM D-Ala or L-Ala. Due to their much
higher vancomycin sensitivity, vanX mutants were tested with 1, 5, 10, 50,
and 100 M D-Ala and L-Ala.
Five vanA-positive Enterococcus faecium strains collected in 2011 and
2014 from patients at the Erasmus University Medical Centre, Rotterdam,
The Netherlands, were used. The presence of the vanA gene was con-
firmed by real-time PCR with the Light Cycler 480 instrument (Roche
Diagnostics, Almere, The Netherlands) with primers vanA F1 and vanA
R1 and a vanA-specific probe labeled with 6-fluorescein amidite (FAM) at
the 5= end and with black hole quencher (BHQ1) at the 3= end. The
resistance profiles of these isolates (see Table S2 in the supplemental ma-
terial) were determined using the Vitek II (bioMérieux) system AST-
P586. To determine the MIC of vancomycin against E. faecium, cells were
grown overnight on tryptic soy agar (TSA) blood agar plates (Becton
Dickinson, Breda, The Netherlands) and suspended in 0.9% NaCl until
the optical density at 600 nm (OD600) reached 0.5 ( 0.05). Of this sus-
pension, 10 l was dispensed into wells of sterile flat-bottom 96-well
polystyrene tissue culture plates (Greiner Bio-One, Alphen a/d Rijn, The
Netherlands) containing serial dilutions of vancomycin in 190 l of a 1:1
mixture of fetal bovine serum (FBS) (Gibco, Bleiswijk, The Netherlands)
and Iscove’s modified Dulbecco’s medium (IMDM) (without phenol red;
Gibco, Bleiswijk, The Netherlands) and in the presence or absence of 50
mM D-alanine (Alfa Aesar, Ward Hill, MA, USA). Plates were incubated
for 18 to 24 h at 37°C and MIC values determined visually following the
CLSI guidelines or by absorbance at 600 nm.
Constructs for gene disruption and complementation. Deletion mu-
tants were constructed according to a method described previously (48).
For deletion of ddl, the nucleotide (nt) 948/20 and 1173/2638
regions relative to the translational start of ddl were amplified by PCR
using primer pairs ddl_LF-ddl_LR, and ddl_RF-ddl_RR, using PCR con-
ditions as described previously (49). The left and right flanks were cloned
into the multicopy vector pWHM3 (50), which is highly unstable in Strep-
tomyces and therefore allows efficient gene disruption (51). Subsequently,
the apramycin resistance cassette aac(3)IV flanked by loxP sites was
cloned into the engineered XbaI site to create deletion construct
pGWS1152. The same strategy was used to create a construct for the
deletion of vanX. In this case, the nt 1477/30 and 572/2035 re-
gions relative to the start of vanX (SCO3596) were PCR amplified using
primer pairs vanX_LF-vanX_LR and vanX_RF-vanX_RR (see Table S3 in
the supplemental material). Insertion of an aac(3)IV-loxP site in the en-
gineered XbaI site generated deletion construct pGWS1164. The presence
of loxP sites allows the efficient removal of the apramycin resistance cas-
sette from the chromosome following the introduction of plasmid
pUWLCRE, which expresses the Cre recombinase (52).
Complementation constructs. A construct for the genetic comple-
mentation of ddlwas made by amplifying the promoter and coding region
of ddl using primers ddlcomp_F and ddlcomp_R (nt 573/1184 rela-
tive to the start of ddl) (see Table S3 in the supplemental material) and
inserted as an EcoRI/BamHI fragment in pHJL401 (53), a highly stable
low-copy-number vector that is well suited for genetic complementation
(54), resulting in pGWS1159.
Fluorescence microscopy. Samples were grown for 18 h in liquid
NMMP, after which a sample was taken from the culture to stain with
BODIPY-FL vancomycin (Vanco-FL) as described previously (55). Equal
amounts of unlabeled vancomycin and Vanco-FL were added to the sam-
ple to a final concentration of 1g/ml, and this was incubated for 10 to 20
min at 30°C. Directly after taking the first sample, 50 mM D-Ala was added
to the medium, and the sample was left to grow for another hour before
imaging the effect of added D-Ala. Imaging was done as described previ-
ously (56). A Zeiss observer with a Plan-Neofluar 40/0.9 lens was used,
and green fluorescent protein (GFP) was excited at a wavelength of 488
nm and observed at 515 nm with filter BP505-550, with the illumination
power set to 7.5%. The images were analyzed with ImageJ, and all the
fluorescent images were processed identically. The final figure was made
with Adobe Photoshop CS6.
Isolation of cytoplasmic PG precursors. For cytoplasmic peptidogly-
can (PG) precursor isolation and identification, we used a modification of
the method described previously by Hong and colleagues (27). Where
applicable, 10 g vancomycin was added to the strains at the moment of
inoculation. The strains were grown in NMMP (1% [wt/vol] mannitol, 50
mM MgCl2) until mid-log phase (OD of 0.3 to 0.4), and mycelia were
harvested by centrifugation at 4°C and washed in 0.9% NaCl. Mycelia
were extracted with 5% cold trichloroacetic acid (TCA) for 30 min at 4°C.
This product was centrifuged and the supernatant desalted on a Sephadex
G-25 column (Illustra NAP-10 columns; GE Healthcare, Pittsburgh, PA)
and concentrated by rotary evaporation. The concentrated precursors
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were dissolved in high-pressure liquid chromatography (HPLC)-grade
water and separated by liquid chromatography-mass spectrometry (LC-
MS) using a gradient of 0 to 20% acetonitrile in water with 0.1% trifluo-
roacetic acid (TFA). The elution was monitored at 254 nm and by the sizes
eluted (m/z 1193.8 to 1195.3).
For the measurement over time, the protocol was adjusted in the fol-
lowing way. NMMP cultures (300 ml) were grown until exponential phase
(OD of 0.3 to 0.4), at which point a 10-ml sample was taken (t 0) and 50
mM D-Ala or L-Ala was added to the original culture, followed by further
sampling after 1, 5, 15, 30, 60, 120, and 180 min. Samples were rapidly
filtered with a vacuum pump and washed with 0.9% (wt/vol) NaCl, and
mycelia were scraped off the filter and transferred to 5% TCA.
RESULTS
D-Ala reduces vancomycin resistance. The bifunctional activity
and structural analysis of the VanA enzyme imply that it can use
both D-Lac and D-Ala as substrates (40, 57), suggesting that D-Ala
might be able to compete with D-Lac in the active site of the en-
zyme. To test the applicability of this concept, we used the natu-
rally vancomycin-resistant S. coelicolor M145 as a model system.
The strain was grown on minimal medium (MM) agar plates with
increasing concentrations of D-Ala and vancomycin. D-Ala was
added at a concentration of 5, 10, or 50 mM and the effect on the
MIC of vancomycin assessed. As controls we added either L-Ala or
neither alanine stereoisomer. In the absence of added amino acids,
the MIC of vancomycin against S. coelicolor was 128 g/ml. Sup-
plementing the medium with up to 50 mM L-Ala did not have any
effect on the susceptibility to vancomycin (Table 1; see Fig. S1 in
the supplemental material). Sensitivity to vancomycin increased
significantly when D-Ala was added; at 10 mM D-Ala, the MIC
decreased to 32 g/ml (4-fold reduction), while at 50 mM D-Ala,
the MIC was reduced to 4g/ml (32-fold reduction) (Table 1; see
Fig. S1 in the supplemental material). This supports the concept
that D-Ala can reduce VanA-based vancomycin resistance, pre-
sumably by competing with the substrate D-Lac at the active site of
the VanA enzyme (58, 59).
Creation of a vancomycin-independentddlmutant. To study
the molecular basis of this effect in more detail, a strain that de-
pends on vanA for the synthesis of the D-Ala–D-Ala dipeptide and
thus for cell wall synthesis was required. The wild-type gene for
D-Ala–D-Ala ligase is ddl (SCO5560 in S. coelicolor), which is es-
sential for normal growth, but its absence can be rescued by the
vancomycin-inducible expression of vanA, the only other paral-
ogue of ddl in the S. coelicolor genome (40, 60). To allow direct
comparison with other mutants related to GlcNAc and cell wall
metabolism previously made in our laboratory (61–63), a ddl
(SCO5560)-null mutant was created in our specific S. coelicolor
M145 laboratory host, thereby ensuring that all of the mutants
have the same isogenic background. This was done by replacing
the entire ddl coding region by the apramycin resistance cassette
(aacC4) via homologous recombination and subsequent removal
to leave an in-frame deletion of ddl in the genome. The aacC4 gene
was flanked by loxP sites, allowing the subsequent removal by
expression of the Cre recombinase, resulting in a markerless dele-
tion mutant of ddl (see Materials and Methods). To compensate
for the absence of D-Ala–D-Ala, the ddl mutant was created in the
presence of vancomycin, so as to elicit the production of the alter-
native precursor dipeptide D-Ala–D-Lac by VanA (42). Many can-
didate ddl null mutants were obtained, all of which failed to grow
in the absence of vancomycin and showed normal sporulation.
One of these strains was selected for further characterization.
The absence of ddl in this mutant was confirmed by PCR (data
not shown). As expected, the ddl mutant could grow only on
agar plates with vancomycin (Fig. 1). Introduction of plasmid
pGWS1159, which expresses the ddl gene from its own pro-
moter, into the ddl-null mutant restored normal development
and growth in the absence of D-Ala (data not shown).
To allow study of the sensitivity of VanA to inhibitory mole-
cules regardless of the presence or absence of vancomycin, we
selected for suppressor mutants by plating spores (107 CFU) of the
TABLE 1 Effect of D-Ala on the MICs of vancomycin against S.
coelicolor M145 and its mutant LAG2
Strain
Vancomycin MIC (g/ml) with:
No amino
acid
D-Ala L-Ala
5
mM
10
mM
50
mM
5
mM
10
mM
50
mM
M145 128 32 32 4 128 128 128
	ddl mutanta 128 32 32 4 128 128 128
LAG2 128 64 32 4 128 128 128
a The ddl null mutant is not viable on medium without vancomycin but had an MIC
identical to that of M145.
FIG 1 Effect of D-Ala on growth of S. coelicolor M145 and derivatives. The strains are S. coelicolor M145 (parental strain), its vanX mutant, suppressor mutant
LAG2, LAG2 	vanX and M145 	ddl. Strains were streaked on MM with, from left to right, no additives (control), 10 g/ml vancomycin, 10 mM D-Ala, or 10
g/ml vancomycin plus 10 mM D-Ala. The ddl mutant fails to grow in the absence of vancomycin, a phenotype that is suppressed in LAG2 due to constitutive
expression of the van resistance cluster. Note the high sensitivity of the vanX-null mutants of M145 and LAG2 to the combination of vancomycin and D-Ala.
Plates were incubated for 3 days at 30°C.
van der Aart et al.
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ddl-null mutant onto SFM agar plates lacking vancomycin, so as
to select for suppressors with constitutive expression of the van-
comycin resistance cluster. This yielded a small number of spon-
taneous suppressor mutants, which occurred at a frequency of
around 106. These constitutively expressed the vancomycin re-
sistance cluster, as this is a requirement to compensate for the
absence of ddl. One of the suppressor mutants was selected and
designated LAG2 (Fig. 1).
DNA sequencing of the vancomycin resistance genes
vanRSJKHAX of strain LAG2 revealed that the insertion element
IS466A (SCO3469) (16, 64, 65) had inserted at nt 55 relative to the
translational start of vanS, causing loss of function. This sponta-
neous integration event in vanS had been observed before in both
Streptomyces and Enterococcus strains and results in constitutive
upregulation of the vancomycin resistance cluster (37, 66, 67).
The ddl suppressor mutant LAG2 had a level of vancomycin resis-
tance similar to that of the parental strain, with an MIC of 128
g/ml (Table 1). Similar to what is seen for wild-type cells, addi-
tion of L-Ala did not affect the MIC for vancomycin, while addi-
tion of D-Ala decreased the MIC to 4 g/ml when 50 mM D-Ala
was added to the agar plates (Table 1). Thus, while LAG2 consti-
tutively expresses the vancomycin resistance cluster, it has a van-
comycin MIC comparable to that for wild-type cells, which in
both cases could be strongly reduced by the addition of D-Ala.
Deletion of vanX amplifies the effect of D-Ala on vancomycin
sensitivity. We then wondered if targeting vanX could further
potentiate the effect of D-Ala as inhibitor of vancomycin resis-
tance. VanX hydrolyzes D-Ala–D-Ala, thereby counteracting the
accumulation of wild-type precursors and supporting vancomy-
cin resistance (68, 69). A vanX-null mutant was created using a
strategy similar to that for ddl, replacing the coding region of vanX
by the apramycin resistance cassette aacC4. The mutant was cre-
ated from both the parental strain S. coelicolor M145 and its ddl
suppressor mutant LAG2, generating M145 	vanX and LAG4
(LAG2 	vanX), respectively.
The respective vanX mutants of M145 and LAG2 grew on me-
dium supplemented with 10g/ml vancomycin and 10 mM D-al-
anine but failed to grow on medium containing both vancomycin
and D-alanine at a concentration where M145 and LAG2 did not
show sensitivity to vancomycin (Fig. 1). LAG2 	vanX produced
20% wild-type precursors prior to the addition of D-Ala. This
strongly suggests that VanA produces a significant amount of
D-Ala–D-Ala in vivo, which accumulates in the absence of VanX.
Consistent with this idea, the MIC of vancomycin was lower for
the vanX mutant, namely, 32 g/ml for the vanX mutant and 64
g/ml for LAG2 	vanX, compared to 128 g/ml for the parental
strain M145 (Table 2).
In wild-type cells, 50 mM D-Ala was required to reduce the
MIC for vancomycin to 4g/ml. However, only 50M D-Ala was
required to reduce the MIC of vancomycin for the vanXmutant to
1 g/ml. This spectacular difference means that D-Ala is around
4,000 times more effective in the absence of the D-Ala–D-Ala pep-
tidase activity of VanX. This is consistent with the very strong
accumulation of wild-type precursors in vanX-null mutants com-
pared to the vanX-positive parental strain.
Analysis of PG precursors. In order to get more insight into
the synthesis of vancomycin-sensitive (i.e., wild-type) or vanco-
mycin-resistant peptidoglycan (PG), the pool of PG precursors
was analyzed by liquid chromatography coupled to mass spec-
trometry (LC-MS) (58, 60, 70) When cells produce wild-type PG,
only MurNAc pentapeptides with a D-Ala–D-Ala terminus are de-
tected, while vancomycin-resistant PG precursors have a D-Ala–
D-Lac terminus. Wild-type precursors ending with D-Ala–D-Ala
are characterized by a peak with a monoisotopic mass of 1,994 Da
and a retention time of around 7.2 min, while vancomycin-insen-
sitive precursors ending with D-Ala–D-Lac are characterized by a
peak of a monoisotopic mass of 1,995 Da and a significantly higher
retention time of around 8.2 min (Fig. 2A).
In extracts from the parental strain grown in the absence of
vancomycin, only wild-type precursors were observed (Fig. 2B).
As expected, when S. coelicolor M145 was grown in the presence of
10g/ml vancomycin, the vast majority of the precursors (91.5%)
represented the vancomycin-insensitive variant. Similarly, 95.7%
of the precursors from the ddl null mutant grown in the presence
of vancomycin contained the terminal D-Ala–D-Lac dipeptide
(Fig. 2B). This indicates that VanA produces a low level of the
D-Ala–D-Ala dipeptide. In the ddl suppressor mutant LAG2,
which constitutively expresses the vancomycin resistance gene
cluster, nearly all PG precursors terminated with D-Ala–D-Lac
(99.8% and 99.7% for cultures grown with and without vancomy-
cin, respectively) (Fig. 2B). We then wondered how D-Ala would
affect the accumulation of wild-type precursors over time in the
suppressor mutant. The constitutive expression of the vancomy-
cin resistance cluster in the suppressor mutant allows growth of
ddl-null mutants without the need for vancomycin and ensures
that the result is caused by substrate competition and not by a
difference in the expression of the vancomycin resistance cluster.
For the time-lapse experiment, 300-ml NMMP cultures were sup-
plemented with either D-Ala or L-Ala (control) at a 50 mM end
concentration, and 10-ml samples were collected prior to and 1, 5,
15, 30, 60, 120, and 180 min after the addition of either alanine
stereoisomer. Prior to the addition of D-Ala or L-Ala (t 0), LAG2
did not accumulate any wild-type precursors. However, addition
of 50 mM D-Ala resulted in the production of small amounts of
wild-type precursor (1%) within 1 min. After 15 min this amount
had increased to 4%, which appeared to be close to the maximum,
with levels of wild-type precursors never exceeding 5%. L-Ala did
not result in detectable levels of wild-type precursors in LAG2.
Strikingly, analysis of PG precursors in vanX-null mutants re-
vealed that the addition of even low levels of D-Ala facilitated the
accumulation of high levels of wild-type precursors, up to as much
as 80% wild-type precursors at 3 h after the addition of D-Ala (Fig.
2). This supports the notion that in the absence of VanX, wild-type
precursors are incorporated into the cell wall much more fre-
quently, with increased sensitivity to vancomycin as a conse-
quence.
Visualization of vancomycin binding by fluorescence mi-
croscopy. To qualitatively determine the ability of vancomycin to
TABLE 2 MICs of vancomycin against S. coelicolor vanX mutants with
D-Ala
Strain
Vancomycin MIC (g/ml) with:
No amino
acid
D-Ala L-Ala
10
M
50
m
100
M
10
M
50
M
100
M
M145 	vanX 32 16 1 1 32 32 32
LAG2 	vanX 64 32 8 2 32 32 32
Reducing Vancomycin Resistance
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FIG 2 LC-MS analysis of peptidoglycan precursors. (A) Example peak profile and corresponding precursors of S. coelicolor M145 grown with vancomycin,
with the peak area corresponding to a precursor terminating in D-Ala–D-Ala shown in black and the peak corresponding to a precursor terminating in
D-Ala–D-Lac in gray. (B) Ratio (%) of wild-type (black) and vancomycin-resistant (gray) precursors in S. coelicolor M145, its ddl null mutant, and
suppressor mutant LAG2, grown with or without vancomycin (10g/ml). The ddl mutant is shown only with vancomycin, as it fails to grow in its absence.
LAG2 with and without vancomycin has less than 1% wild-type (vancomycin-sensitive) peptidoglycan. Strains were grown with or without vancomycin
to an OD of 0.3 to 0.4 before harvesting. (C) Accumulation of wild-type and vancomycin-resistant precursors over time in LAG2 and LAG2 	vanX. The
samples were grown to an OD of 0.3 to 0.4 prior to the addition of 50 mM D-Ala. Samples were taken prior to (0) or 1, 5, 15, 30, 60, 120, or 180 min after
the addition of D-Ala. (D) Same as for panel C but with L-Ala instead of D-Ala. Bars representing the precursors are shown as percentages (with the total
set to 100%).
van der Aart et al.
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bind to the cell walls of different Streptomyces strains and also
visualize the effect of D-Ala, mycelia of S. coelicolor were fluores-
cently stained with BODIPY-FL vancomycin (Vanco-FL). In van-
comycin-sensitive bacteria, vancomycin localizes in foci at sites of
de novo cell wall synthesis (55). In S. coelicolor, which grows by tip
extension (71), these sites are in particular the hyphal tips and cell
division septa.
While hyphae of S. coelicolor M145 were stained well by
Vanco-FL, hardly any Vanco-FL bound to the hyphae of strains
constitutively expressing vancomycin resistance (LAG2 or
LAG2	vanX) (Fig. 3A). However, addition of D-Ala resulted in
marginal staining by Vanco-FL of the LAG2 hyphal tips (Fig.
3B); in contrast, its vanX mutant derivative LAG4 was stained
very well, in line with the strongly enhanced vancomycin sen-
sitivity of the mutant (Fig. 3).
Taken together, our mutational, microscopy, and LC-MS ex-
periments show that D-Ala effectively and specifically enhances
the sensitivity of vancomycin-resistant S. coelicolor to vancomycin
by allowing accumulation of wild-type cell wall precursors and
thus binding of vancomycin to sites of active cell wall biosynthesis.
This effect was strongly enhanced in vanX mutants (which lack
D-Ala–D-Ala peptidase activity).
Analysis of the effect of D-Ala on the MICs of clinical isolates
of VRE. Having established that D-Ala enhances the efficacy of
vancomycin against vancomycin-resistant S. coelicolor, we then
assessed its effect on the resistance of vanA-positive clinical iso-
FIG 3 Fluorescence micrographs of Vanco-FL-stained hyphae. To analyze vancomycin binding, S. coelicolor strains M145, M145 	vanX, LAG2, and LAG2
	vanX were grown in liquid NMMP for 12 h and continued to grow for 1 h in the absence (A) or presence (B) of 50 mM D-Ala. Mycelia were then stained with
Vanco-FL and imaged. Top panels, fluorescence micrographs (inverted grey scale); bottom panels, corresponding light images. S. coelicolor M145 and its vanX
mutant were readily stained by Vanco-FL. Constitutively vancomycin-resistant strain LAG2 was not stained by Vanco-FL in the absence of D-Ala and showed
some binding after the addition of D-Ala. Extensive Vanco-FL staining was seen for LAG2 	vanX only after the addition of D-Ala. Insets show magnifications of
the areas indicated by arrows in the respective images. Scale bars, 10 m.
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lates of E. faecium. MIC values were calculated by testing a serial
(2-fold) dilution of vancomycin in the presence or absence of
D-Ala in triplicate (Table 3). Similar to what was seen for S. coeli-
color, addition of 50 mM D-Ala to the growth medium resulted in
a strong increase in the efficacy of vancomycin against all clinical
isolates, with reduction of 4 to 7 dilution steps. Even in the worst
cases, the MIC of vancomycin was still reduced 16- to 32-fold
(from 4,096 g/ml to 256 g/ml or 128 g/ml), while we also
noted a further decrease to values as low as 16 g/ml for strain
vanA10. This value corresponds to intermediate resistance.
DISCUSSION
With the rapid spread of vancomycin resistance, new efforts are
needed to maintain this last-resort antibiotic as a clinical drug
against multidrug-resistant bacterial infectious diseases. So far,
attempts have included engineering VanX inhibitors (26, 41, 72)
or reengineering vancomycin itself to target not only the cell wall
precursors with D-Ala–D-Ala termini but also those ending with
D-Ala–D-Lac (73). As a basis to develop new approaches to target
vancomycin resistance, we studied the model organism S. coeli-
color, which has a set of vancomycin resistance genes very similar
to those of the pathogenic VRE (34).
VanA, a variant of Ddl that ligates D-Ala to D-Lac to form
D-Ala–D-Lac, plays a key role in vancomycin resistance. VanA is a
bifunctional enzyme which can produce both D-Ala–D-Lac and
D-Ala–D-Ala, with the affinity for either D-Lac or D-Ala as a sub-
strate being highly dependent on the substrate and pH (45, 74, 75).
The extracellular addition of high concentrations of D-Ala results
in increased accumulation of wild-type cell wall precursors and
consequently the build-up of vancomycin-sensitive PG, due to
competition with D-Lac at the active site of VanA, while supple-
menting D-Lac leads to a high abundance of precursors terminat-
ing in D-Ala–D-Lac (58, 60, 70). Supplementing cultures of a con-
stitutively vancomycin-resistant variant of S. coelicolor M145 with
excess D-Ala resulted in accumulation of up to 5% wild-type pre-
cursors. While interesting, the effect is too low to be effective in
treatment of vancomycin-resistant pathogens. We have also tested
whether the effect of D-Ala was apparent for A40926, the natural
precursor of the expanded-spectrum semisynthetic glycopeptide
antibiotic dalbavancin isolated from Nonomuraea sp. strain
ATCC 39727 (76). Perhaps surprisingly, the efficacy of A40296
was not affected by the addition of D-Ala (data not shown). This
suggests that its mode of action and the mechanism of resistance
are different from those of vancomycin, despite the fact that het-
erologous expression of the vanHAX cluster increases resistance to
A40926 in Nonomuraea spp. (77).
Importantly, the effect of D-Ala as enhancer of the efficacy of
vancomycin was massively enhanced in the absence of VanX, with
up to 80% of the precursors accumulated in vanX-null mutants
containing the wild-type dipeptide. As support of the biochemical
data, active incorporation of wild-type precursors at apical sites
was visualized with Vanco-FL, which fluorescently stains all sites
of active cell wall synthesis, i.e., the hyphal tips and newly synthe-
sized septa. While wild-type cells and vanX mutant cells were
stained very well by Vanco-FL, derivatives with constitutive van-
comycin resistance were hardly stained. However, addition of
D-Ala recovered fluorescence even to cells with constitutive van-
comycin resistance, which is indicative of the incorporation of
wild-type cell wall material concomitant with increased sensitivity
to vancomycin. Other ways D-Ala could affect vancomycin sensi-
tivity could be by DD-transpeptidases in the periplasm substituting
D-Lac for D-Ala on the precursors or by inhibition of the expres-
sion of D-Lac dehydrogenases by D-Ala. The strong direct correla-
tion between PG precursor accumulation and vancomycin bind-
ing (as determined by imaging fluorescent vancomycin) argues
against a major influence of DD-transpeptidases in this process.
The fluorescence correlated with the level of wild-type cell wall
precursors in the various strains, and this method therefore offers
rapid qualitative assessment of vancomycin sensitivity, which
could be applied in high-throughput screening for compounds
that potentiate vancomycin resistance. By combining the precur-
sor analysis and staining with Vanco-FL, it is also clear not only
that D-Ala is incorporated in PG precursors but that the pentapep-
tides terminating in D-Ala–D-Ala are displayed at the cell surface
and incorporated into the mature cell wall. A question which re-
mains, though, is which amount of vancomycin-sensitive PG
would be sufficient to regain sensitivity against vancomycin.
Previous work indicated that the deletion of vanX increases the
sensitivity to vancomycin (70). However, as our work shows, sig-
nificant changes in the MIC are brought about only when D-Ala is
added as competitive inhibitor for D-Lac. This change in response
to the deletion of vanX may well depend on the target organism,
which is underlined by the differential effect of added D-Ala on the
MICs of independent clinical VRE isolates. Based on the findings
presented in this work, we propose a model for vancomycin resis-
tance in which the catalytic activity of VanA depends largely on the
available substrate (Fig. 4). In the presence of excess D-Ala, VanA
is bifunctional and synthesizes both D-Ala–D-Ala and D-Ala–D-
Lac, but the wild-type dipeptide is then cleaved by the VanX pep-
tidase. However, excess D-Ala will result in such large amounts of
D-Ala–D-Ala that VanX cannot degrade the dipeptides sufficiently
rapidly to avoid their use as a substrate by VanA, thus resulting in
low levels of wild-type lipid II. As a result, a small proportion of
wild-type PG is produced, giving enhanced vancomycin sensitiv-
ity. In the absence of vanX, the addition of even very small
amounts of D-Ala (10 to 50 M instead of 10 to 50 mM) already
led to strong accumulation of wild-type precursors and a drop in
the MIC of vancomycin to values as low as 1 g/ml. This is well
within the range of clinical sensitivity.
How can the concepts developed in this work be implemented
into approaches to counteract vancomycin-resistant Gram-posi-
tive pathogens such as VRE and vancomycin-resistant S. aureus
(VRSA)? The high sensitivity of vanX-null mutants to the combi-
nation of vancomycin and D-Ala strongly suggests that the com-
bined treatment with vancomycin and D-Ala will be particularly
effective in combination with molecules that perturb the bioactiv-
ity of VanX. VanX inhibitors have been described in the literature,
TABLE 3 MICs of vancomycin against VRE in the presence or absence
of D-Ala
Strain
Vancomycin MIC
(g/ml) with D-Ala at:
Dilution step reduction0 mM 50 mM
vanA1 4,096 256 4
vanA2 4,096 256 4
vanA3 4,096 128 5
vanA4 4,096 128 5
vanA10 2,048 16 7
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but their effect was limited (26, 41, 72, 78, 79). Based on the data
presented here, this is likely explained by the fact that the effect of
a vanX deletion without additional D-Ala is very limited, decreas-
ing the MIC by only 2-fold in this work. Similarly, the data also
point out that VanX inhibitors that have been or will be developed
in the future should be (re)tested in the presence of added D-Ala,
as this largely augments their efficacy. Strains that depend on the
vancomycin resistance cluster for growth thereby are candidates
as screening hosts for a high-throughput screen of small molecules
that target vancomycin resistance. This may prove to be an impor-
tant asset in the hunt for drugs that counteract vancomycin-resis-
tant pathogens such as VRE and VRSA.
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